Fronto-central resting-state 15-29Hz transient beta events change with therapeutic transcranial magnetic stimulation for posttraumatic stress disorder and major depressive disorder - Morris, Alexander T.; Temereanca, Simona; Zandvakili, Amin; Thorpe, Ryan; Sliva, Danielle D.; Greenberg, Benjamin D.; Carpenter, Linda L.; Philip, Noah S.; Jones, Stephanie R. (medRxiv, 2023)
Repetitive transcranial magnetic stimulation (rTMS) is an established treatment for major depressive disorder (MDD) and shows promise for posttraumatic stress disorder (PTSD), yet effectiveness varies. Electroencephalography (EEG) can identify rTMS-associated brain changes. EEG oscillations are often examined using averaging approaches that mask finer time-scale dynamics. Recent advances show some brain oscillations emerge as transient increases in power, a phenomenon termed “Spectral Events,” and that event characteristics correspond with cognitive functions. We applied Spectral Event analyses to identify potential EEG biomarkers of effective rTMS treatment. Resting 8-electrode EEG was collected from 23 patients with MDD and PTSD before and after 5Hz rTMS targeting the left dorsolateral prefrontal cortex. Using an open-source toolbox (https://github.com/jonescompneurolab/SpectralEvents), we quantified event features and tested for treatment associated changes. Spectral Events in delta/theta (1-6 Hz), alpha (7-14 Hz), and beta (15-29 Hz) bands occurred in all patients. rTMS-induced improvement in comorbid MDD PTSD were associated with pre-to post-treatment changes in fronto-central electrode beta event features, including frontal beta event frequency spans and durations, and central beta event maxima power. Furthermore, frontal pre-treatment beta event duration correlated negatively with MDD symptom improvement. Beta events may provide new biomarkers of clinical response and advance the understanding of rTMS.Competing Interest StatementIn the last three years, NSP has received clinical trial support (through VA contracts) from Wave Neuro and Neurolief, Inc. LLC has received support (through contracts with Butler Hospital) from Neuronetics, Affect Neuro, Janssen, Neurolief, and Nexstim. ATM, ST, AZ, RT, DDS, BDG, and SRJ have no conflicts of interest.Clinical TrialNCT02273063Funding StatementOriginal trial supported in part by Neuronetics, Inc., through an investigator-initiated grant to LLC (Butler Hospital). In the last three years, NSP has received clinical trial support (through VA contracts) from Wave Neuro and Neurolief, Inc. LLC has received support (through contracts with Butler Hospital) from Neuronetics, Affect Neuro, Janssen, Neurolief, and Nexstim. ATM, ST, AZ, RT, DDS, BDG, and SRJ have no conflicts of interest. Effort on this manuscript was supported in part by VA grants I50 RX002864, IK2 CX002115, and I01 CX002088; NIH grants P20 GM130452.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients met clinical and safety criteria for rTMS. Concurrent psychotropic medications and ongoing psychotherapy were continued at stable regimens during participation. Written informed consent was obtained for all study procedures, which were approved by the VA Providence and Butler Institutional Review Boards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated during and/or analyzed during the current study are not publicly available and may be available from the corresponding author on reasonable request and subject US Department of Veterans Affairs rules on data sharing.